Nektar Therapeutics (NASDAQ:NKTR) CFO Sells $513,000.00 in Stock

Share on StockTwits

Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $20.52, for a total transaction of $513,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Gil M. Labrucherie also recently made the following trade(s):

  • On Friday, August 16th, Gil M. Labrucherie sold 5,063 shares of Nektar Therapeutics stock. The shares were sold at an average price of $18.15, for a total transaction of $91,893.45.
  • On Wednesday, August 14th, Gil M. Labrucherie sold 25,000 shares of Nektar Therapeutics stock. The shares were sold at an average price of $17.79, for a total transaction of $444,750.00.
  • On Wednesday, July 10th, Gil M. Labrucherie sold 25,000 shares of Nektar Therapeutics stock. The shares were sold at an average price of $34.57, for a total transaction of $864,250.00.

Shares of NASDAQ:NKTR traded up $0.96 during midday trading on Friday, reaching $17.09. The company had a trading volume of 2,509,851 shares, compared to its average volume of 5,029,829. The company’s 50 day moving average price is $18.25 and its 200 day moving average price is $28.44. The company has a current ratio of 14.09, a quick ratio of 13.97 and a debt-to-equity ratio of 0.22. The stock has a market cap of $2.93 billion, a P/E ratio of 4.52 and a beta of 2.65. Nektar Therapeutics has a 52-week low of $15.84 and a 52-week high of $51.28.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.17. The company had revenue of $23.32 million for the quarter, compared to the consensus estimate of $26.65 million. Nektar Therapeutics had a negative net margin of 354.90% and a negative return on equity of 25.25%. The firm’s quarterly revenue was down 97.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.33 EPS. Research analysts forecast that Nektar Therapeutics will post -2.85 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Crossmark Global Holdings Inc. lifted its holdings in Nektar Therapeutics by 2.2% during the second quarter. Crossmark Global Holdings Inc. now owns 14,244 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 301 shares during the last quarter. Northwestern Mutual Investment Management Company LLC lifted its holdings in Nektar Therapeutics by 1.5% during the first quarter. Northwestern Mutual Investment Management Company LLC now owns 26,456 shares of the biopharmaceutical company’s stock valued at $889,000 after purchasing an additional 395 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in Nektar Therapeutics by 3.0% during the second quarter. CIBC Asset Management Inc now owns 14,059 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 403 shares during the last quarter. TD Asset Management Inc. lifted its holdings in Nektar Therapeutics by 0.5% during the first quarter. TD Asset Management Inc. now owns 84,241 shares of the biopharmaceutical company’s stock valued at $2,830,000 after purchasing an additional 427 shares during the last quarter. Finally, Mason Street Advisors LLC increased its position in shares of Nektar Therapeutics by 1.8% during the first quarter. Mason Street Advisors LLC now owns 24,838 shares of the biopharmaceutical company’s stock valued at $835,000 after buying an additional 436 shares during the period. 93.26% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have commented on NKTR shares. Cowen set a $43.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a report on Thursday, September 26th. ValuEngine upgraded shares of Nektar Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. HC Wainwright set a $24.00 price target on shares of Nektar Therapeutics and gave the company a “hold” rating in a research note on Monday, September 30th. BMO Capital Markets reduced their price target on shares of Nektar Therapeutics from $75.00 to $41.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, Jefferies Financial Group downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the company from $59.00 to $23.00 in a research note on Friday, August 9th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $37.00.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Story: Cost of Equity For A Business, Investors

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.